Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer
We performed RNA-seq to evaluate the consequence of saracatinib's effects on androgen receptor residue Y534 as it pertains to Androgen Receptor gene signatures Overall design: Performed gene expression profiling analysis using data obtained from RNA-seq of 1 cell line at 4 treatment groups. In duplicate